Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOPIC: Imiquimod for High-grade Cervical Intraepithelial Neoplasia
NCT02329171Phase 3Terminated
- Sponsor
- Maastricht University Medical Center+
- Start
- Dec 2014
- Primary completion
- Jun 2016
- Modality
- Nucleic Acid-Directed Small Molecules, Irreversible Covalent Inhibitors, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of imiquimod in cervical intraepithelial neoplasia (CIN) (2 arms), sponsored by Maastricht University Medical Center+. Primary endpoints: Histological disease regression at 20 weeks and Baseline biomarker profile predicting clinical response at 20 weeks. Started Dec 2014; status: terminated.
02
Drugs
imiquimod
03
Conditions
cervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on NCT02329171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02329171.